Hydrofarm Holdings Group Announces Termination of $109 Million Senior Secured Term Loan in Connection with Pricing of Aggregate $8.3 Million Registered Direct Offering and Concurrent Private Placement

The loan-satisfaction agreements exchange debt for convertible preferred shares and warrants, with conversion and exercise subject to shareholder approval.

Rhea-AI Summary

Hydrofarm Holdings Group (HYFM) agreed to an approximately $8.3 million financing alongside an equity exchange to satisfy its $109 million term loan. Expected gross proceeds are before placement fees and expenses; closing is expected on or about October 27, 2026. The registered offering covers 1,599,400 shares at $0.905. The private placement covers 7,611,575 shares or pre-funded warrants in lieu thereof, plus 9,210,975 common warrants, at a purchase price of $0.9050. Those common warrants carry a $0.78 exercise price and expire five and a half years after issuance.

To satisfy the loan in full, Hydrofarm agreed to issue 27.5 million convertible preferred shares, each convertible into one common share, and warrants for 27.5 million common shares at $0.78. Preferred conversion and lender-warrant exercise require shareholder approval. CEO Bill Toler and other officers, directors or their affiliates will participate in the financing on the same terms as other investors.

3 points · 2 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

2 major · 6 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Term-loan agreements provide for satisfying the $109 million loan in full through preferred shares and warrants. 27× market cap
• Major point. Forward-looking: it has not happened yet and may not happen.Financing is expected to raise approximately $8.3 million in gross proceeds before fees and expenses. 2× market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.CEO and other officers, directors or affiliates will invest on the same terms as other investors.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Loan exchange adds 27.5 million preferred shares convertible one-for-one and 27.5 million lender warrants exercisable at $0.78, creating potential dilution.
• Major point. Forward-looking: it has not happened yet and may not happen.Private placement adds 7,611,575 shares or pre-funded warrants and 9,210,975 common warrants at a purchase price of $0.9050.
• Minor point. Forward-looking: it has not happened yet and may not happen.Registered offering issues 1,599,400 common shares at $0.905, diluting existing holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Private-placement common warrants add potential dilution at $0.78 per share over five and a half years.
• Minor pointPreferred-share conversion and lender-warrant exercise remain subject to shareholder approval.
• Minor point. Forward-looking: it has not happened yet and may not happen.Financing proceeds are reduced by placement agent fees and offering expenses.

News Explained

Although the headline says the $109 million term loan was terminated, the release ties satisfying it through preferred shares and warrants to the offering’s expected closing; with conversion and exercise subject to shareholder approval, completed loan satisfaction is not established.

Argus 15 min delay 29 alerts

-7.68% vs previous close $0.78 last price 74.1x rel. volume Open Argus

Details

Market move: HYFM -7.68% vs previous close. $8.3M public offering

+4.8% Peak Tracked

-29.4% Trough Tracked

$0.66 – $0.98 Day Range

$3.76M Mkt Cap at Last Price

On Oct 27, the day this news came out, the latest delayed price for HYFM is 7.68% below the previous close. Argus tracked a peak move of +4.8% during the session. Argus tracked a trough of -29.4% from its starting point during tracking. Our momentum scanner has recorded 29 alerts for this stock so far that day. The latest delayed price is $0.78. Relative volume is exceptionally heavy at 74.1x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Term Loan: $109 million Expected gross proceeds: Approximately $8.3 million Registered direct offering shares: 1,599,400 shares +5 more

Term Loan

$109 million

Loan announced as terminated in connection with the offering

Expected gross proceeds

Approximately $8.3 million

Before placement agent fees and offering expenses

Registered direct offering shares

1,599,400 shares

Common stock

Private placement shares

7,611,575 shares

Unregistered common shares or pre-funded warrants in lieu

Common Warrants

9,210,975 warrants

Issued in the concurrent private placement

Common Warrant exercise price

$0.78 per share

Exercise price for each Common Warrant

Preferred shares for Term Loan satisfaction

27.5 million shares

Series 1 Non-Voting Convertible Preferred Stock; conversion subject to shareholder approval

Lender Warrants

27.5 million warrants

Issued to satisfy the Term Loan; exercise subject to shareholder approval

Historical Context

1 past event · Latest: Aug 14

1 event

1. Aug 14

   quarterly results

   24h Move

   -15.0%

   Reported $114.4 million Term Loan in default under forbearance, establishing debt strain addressed by this settlement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, pre-funded warrants, private placement, form s-3, +1 more

5 terms

registered direct offering financial

"purchase price of $0.905 priced at-the-market under Nasdaq rules"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

pre-funded warrants financial

"or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

private placement financial

"In a concurrent private placement, investors also agreed to purchase"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

form s-3 regulatory

"made pursuant to a registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

rule 506 regulatory

"or Rule 506 of Regulation D promulgated thereunder"

A Securities and Exchange Commission rule that lets companies sell securities without registering them with the SEC when they meet certain conditions, commonly used for private placements. It allows issuers to raise unlimited capital from accredited investors and, in some versions, a small number of knowledgeable non‑accredited investors; one version also permits public advertising if the seller takes steps to verify investor credentials. For investors, it signals a private offering with lighter disclosure and different protections than a public stock sale, similar to buying into a private club rather than a publicly traded marketplace.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SHOEMAKERSVILLE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded supplies and equipment for controlled environment agriculture, today announced that it has entered into definitive agreements for the purchase of 1,599,400 shares of common stock in a registered direct offering at a purchase price of $0.905 priced at-the-market under Nasdaq rules. In a concurrent private placement, investors also agreed to purchase 7,611,575 unregistered shares of common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and 9,210,975 common stock purchase warrants (“Common Warrants”) at a purchase price of $0.9050. Each Common Warrant is exercisable for one share of common stock at an exercise price of $0.78 and will expire five and a half years from the issuance date. Total gross proceeds from the offering, before deducting the placement agent fee and offering expenses are expected to be approximately $8.3 million. All of the shares of common stock, Pre-funded Warrants, and Common Warrants are being sold by the Company.

Bill Toler, the Company's Chairman and Chief Executive Officer, as well as additional officers and directors of the Company, or their respective affiliates, will participate in the offering on the same terms as the other investors.

ThinkEquity is acting as sole placement agent and advisor to Hydrofarm in connection with the transactions. The Company intends to use the net proceeds for general corporate purposes. The closing of the offering is expected to occur on or about October 27, 2026, subject to satisfaction of customary closing conditions.

In conjunction with the closing of the offering, the Company has entered into agreements with the holders of its Senior Secured Term Loan (the “Term Loan”) and the agent thereunder to issue 27.5 million shares of Series 1 Non-Voting Convertible Preferred Stock and common stock purchase warrants to purchase 27.5 million shares of common stock (“Lender Warrants”) to satisfy the Company’s Term Loan in full. Each share of Series 1 Non-Voting Convertible Preferred Stock converts into one share of common stock. Each Lender Warrant is exercisable for one share of common stock at an exercise price of $0.78. The conversion of the shares of Series 1 Non-Voting Convertible Preferred Stock and exercise of the Lender Warrants are subject to shareholder approval.

The registered direct offering is being made pursuant to a registration statement on Form S-3 (File No. 333-291444) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) on November 12, 2025 under the Securities Act of 1933, as amended (the “Securities Act”) and declared effective on December 10, 2025, the base prospectus dated December 10, 2025 thereunder and a prospectus supplement to the base prospectus to be filed with the SEC. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41^st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

The concurrent private placement of the common shares, Common Warrants, and Pre-funded Warrants, will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act, or Rule 506 of Regulation D promulgated thereunder. The securities offered and sold by the Company in the private placement have not been registered under the Securities Act, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock, Common Warrants, Pre-funded Warrants, and common stock underlying the Pre-funded Warrants and Common Warrants to be issued in the private placement. Any resale of the Company’s shares under such resale registration statement will be made only by means of a prospectus.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Hydrofarm Holdings Group, Inc.
Hydrofarm is a leading independent manufacturer and distributor of supplies and equipment for controlled environment agriculture, including plant nutrition, growing media, horticultural lighting, and climate control solutions, as well as a broad portfolio of innovative proprietary branded products. The Company manufactures its proprietary plant nutrition and growing media brands at its manufacturing center of excellence in Eugene, Oregon. For nearly 50 years, Hydrofarm has helped growers make growing easier and more productive. The Company’s mission is to empower growers, farmers and cultivators with products that enable greater quality, efficiency, consistency and speed in their grow projects.

Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "believe," "expect," "intend," "anticipate," "plan," "will," "project," "potential" and similar expressions. They include, among others, statements regarding: the completion and timing of the closing of the registered direct offering and concurrent private placement, and the expected gross proceeds and intended use of the net proceeds; the satisfaction and discharge of the Term Loan through the issuance to the holders of the Term Loan of Series 1 Non-Voting Convertible Preferred Stock and Lender Warrants, and the release of related liens; the receipt of stockholder approval for the conversion of the Series 1 Non-Voting Convertible Preferred Stock and the issuance of shares upon exercise of the Lender Warrants; the filing and effectiveness of resale registration statements for the securities issued in the concurrent private placement and to the holders of the Term Loan; and the Company's future financial performance, liquidity and capital allocation plans.

These statements are based on management's current expectations and assumptions. They are subject to risks and uncertainties that could cause actual results to differ materially, including: the risk that the offering does not close when expected or at all, including because customary closing conditions are not satisfied; the risk that the conditions to the termination of the Term Loan are not satisfied on time; the risk that stockholders do not approve the conversion of the Series 1 Non-Voting Convertible Preferred Stock or the issuance of the Lender Warrant shares, or that approval is delayed; the risk that the Company cannot file or obtain effectiveness of the required resale registration statements; the dilution to existing stockholders from the issuance of common stock, Pre-Funded Warrants, Common Warrants, Lender Warrants and Series 1 Non-Voting Convertible Preferred Stock, and from any later conversion or exercise; the impact on the market price of the common stock of future sales of shares; the risk that the Company does not regain or maintain compliance with Nasdaq continued listing requirements; and the other factors described under "Risk Factors" in the Company's Annual Report on Form 10-K, subsequent periodic reports, file with the SEC. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.

ir@hydrofarm.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How will Hydrofarm satisfy its $109 million term loan?

Hydrofarm agreed to issue 27.5 million Series 1 Non-Voting Convertible Preferred shares and warrants to purchase 27.5 million common shares to satisfy the term loan in full. Each preferred share converts into one common share, and each lender warrant has a $0.78 exercise price. Conversion and warrant exercise require shareholder approval.

How much does Hydrofarm expect to raise in its financing?

Hydrofarm expects approximately $8.3 million in gross proceeds from the registered direct offering and concurrent private placement, before placement agent fees and offering expenses. Closing is expected on or about October 27, 2026, subject to customary closing conditions.